Early detection is critical for treatment options of this multisystem disease with cutaneous involvement. Raynaud’s attacks are often in early stages and should always be further evaluated. Advances in research into the pathomechanisms of systemic sclerosis may make it possible to offer new targeted personalized therapies in the not too distant future.
Autoren
- PD Dr. med. habil. Michael Buslau, MSc
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Atherosclerotic Coronary Plaques in High-Risk Patients
Who benefits from preventive PCI?
- Colorectal Cancer
Insulin Resistance, Obesity, and Progression
- Modern asthma therapies
New data on biologics and triple therapy
- From symptom to diagnosis
Abdominal Pain – Focal Nodular Hyperplasia
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Hepatology and Metabolism
The Mediterranean Diet for MASLD/MASH—What the EASL-EASD-EASO Guidelines Specifically Recommend
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?